Head-to-head · Cost-Efficiency Index
CLYR Health vs Invyncible
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
CLYR Health
Shoppers comparing tirzepatide options who account for the post-first-month price increase rather than anchoring on the $149 headline.
Visit CLYR HealthInvyncible
Cost-first shoppers who want compounded GLP-1 combo programs (with B12/glycine) alongside brand Wegovy/Zepbound on one platform.
Visit InvyncibleThe verdict
CLYR Health and Invyncible tie on the Cost-Efficiency Index at 59/100, so neither wins outright on the numbers. For most shoppers we'd start with CLYR Health (ranked #271, a hair above #272) — Shoppers comparing tirzepatide options who account for the post-first-month price increase rather than anchoring on the $149 headline. But Invyncible is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs CLYR Health.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | CLYR Health | Invyncible |
|---|---|---|
| Cost-Efficiency Index | 59/100 | 59/100 |
| Semaglutide / mo | $169/mo (compounded) | $149/mo (0.45 mg dose, compounded with glycine + B12) |
| Tirzepatide / mo | $199/mo (compounded) | $180/mo (2.5 mg weekly, 4-week program, compounded) |
| Semaglutide / yr (modeled) | $2,028 | $1,788 |
| Tirzepatide / yr (modeled) | $2,388 | $2,160 |
| Coverage | Coverage not published | 46 states plus DC |
| Oral / sublingual | No | Yes |
| Brand-name access | Yes | Yes |
| Rank here | #271 | #272 |
CLYR Health
59/100Where the value is
- LegitScript Certified badge displayed
- Named prescribing medical group (MD Integrations, PC) disclosed in Terms of Service
- 503A-licensed compounding pharmacy referenced
The tradeoffs
- Tirzepatide headline price ($149) is an explicit first-month-only rate -- real ongoing cost is $199/month
- Inconsistent states-served claims ('all 50 states' vs. 'ships to 47 states') on the same site
Invyncible
59/100Where the value is
- Publishes real itemized dollar prices for eight separate combo programs plus two brand options directly on the site, no signup required, with the mg vial size named in every dose option
- Sells FDA-approved brand Wegovy ($1,750/mo) and Zepbound ($1,540/mo) alongside compounded options
- Names all six compounding pharmacies with street addresses and phone numbers and lets the patient choose which one fills the prescription
The tradeoffs
- Every listed price is shown as a discount off a much higher struck-through 'list' price, and the page invites further negotiation — reads as permanent anchor pricing
- The entry figure is the smallest vial: plain compounded semaglutide runs $192.50, $262.50 and $350 across its three vial sizes, and the FAQ confirms cost rises with dose
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.